Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts

Daniela Meco, Tiziana Servidei, Riccardo Riccardi, Massimo Zucchetti, Gabriella Cusano, Maurizio D'Incalci, Daniele Forestieri, Claudio Pisano

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

PURPOSE: This study compared the antitumor activity and the pharmacological profile of gimatecan given orally and irinotecan (CPT-11) on pediatric tumor xenografts. EXPERIMENTAL DESIGN: Gimatecan was tested in two neuroblastoma cell lines (SK-N-DZ and SK-N-(BE)2c) and on TE-671 rhabdomyosarcoma cells using two different schedules. We characterized its pharmacokinetic profile in nude mice bearing human SK-N-DZ and TE-671 cell lines. RESULTS: Gimatecan appears to have high plasma disposition. The drug was present in plasma almost completely as the intact lactone form and showed substantial activity in all tumor models. Prolonged daily treatment with low doses of gimatecan produced significant tumor regression in all tumor xenografts. CONCLUSION: The antitumor activity and the promising pharmacological profile indicate gimatecan as an excellent candidate for clinical treatment of pediatric tumors.
Original languageEnglish
Pages (from-to)635-641
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume66
DOIs
Publication statusPublished - 2010

Keywords

  • antitumor activity
  • cancer xenografts
  • gimatecan
  • oral administration
  • pharmacokinetics

Fingerprint

Dive into the research topics of 'Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts'. Together they form a unique fingerprint.

Cite this